Market Overview

Barrington Research Reiterates AtriCure PT


Barrington Research reiterated its AtriCure (NASDAQ: ATRC) $17 price target in a research report published today. Barrington Research has previously given AtriCure an Outperform rating.

In the report, Barrington Research states, " ATRC recently received its panel date for its surgical AF indication for October 26, which is four months earlier than we expected, although there was an outside chance for a November date. ATRC has definitely been very patient and done significantly more and waited significantly longer than originally estimated by the FDA. In our opinion, the evidence has been overwhelming demonstrating that ATRC's products are safe and effective."

Shares of AtriCutre were trading at $10.40 at the time of posting, down 0.19% from Friday's market close.

Posted-In: Barrington ResearchAnalyst Color Price Target Reiteration Analyst Ratings


Related Articles (ATRC)

View Comments and Join the Discussion!

Latest Ratings

ELMDDougherty & Co.Initiates Coverage On12.0
MRNSCantor FitzgeraldAssumes7.0
MNRLCapital One FinancialInitiates Coverage On23.0
SONVertical GroupUpgrades
UNPMorgan StanleyMaintains136.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at

Adobe to Go "Sideways," Investors Should "Avoid the Stock"

European Banks Are Talking To Us